Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Nucynta Gets Nod from FDA

By Drug Discovery Trends Editor | August 29, 2011

Johnson & Johnson said the Food and Drug Administration has approved an extended-release version of the painkiller Nucynta.

The New Brunswick, N.J., conglomerate said Nucynta is an oral medication taken twice daily to manage moderate-to-severe chronic pain in adults.

The immediate-release version of the drug was approved in 2008 and is sold as a treatment for severe acute pain in patients 18 and older.

Last October, J&J said the FDA had requested additional information on the conversion of the extended-release formulation used in prior studies to a version that is designed to increase resistance to breaking or crushing. Nucynta is an opioid and listed as a schedule II drug, meaning it has a high potential for abuse, and users may become psychologically or physically dependent on the drug.

Crushing an opioid often makes it easier to abuse, and there has been a movement in the pharmaceutical industry to make more abuse-resistant opioids.

Janssen Pharmaceuticals Inc., a J&J company, developed Nucynta with Grunenthal GmbH, a privately-held German drug company that discovered the compound.

Date: August 26, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50